“We’ll make it clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House adviser Lael Brainard said on a press call.
In the first trial, at the Peter MacCallum Cancer Center in Australia, CRC patients receiving just divarasib had a 35.9% positive response rate, which was considered extremely promising.
After only two doses, nearly eight out of ten participants in a phase 2 trial by Toronto-based pharmaceutical company Cybin experienced remission from major depressive disorder at six weeks. The company has a planned phase 3 study slated to commence by the end of Q1 2024.
Besides the eyeball, the patient, 46-year-old Aaron James of Hot Springs, Arkansas, also received a partial face transplant and an infusion of donor stem cells to the optic nerve during the more than 20-hour surgery.
Researchers from the Cleveland Clinic have conducted the first human trials of a new drug, lepodisiran, that has the potential to eliminate a risk factor for cardiovascular disease for which there is currently no treatment.
The scientists from Shanghai’s Fudan University implanted new genetic code into a harmless virus and then injected the viruses into the children’s cochlea. They say the experiment has sparked hearing in four out of five children who received the treatment.
Bangladesh has become the first country globally to be validated for elimination of visceral leishmaniasis, a life-threatening neglected tropical disease. The country achieved the elimination target of less than one case per 10,000 population at the sub-district level in 2017 and has sustained it to date.
North Korea introduced a mass measles-rubella immunization program in November 2019. Through this mass immunization activity, achieving more than 99.8% coverage in almost 6 million target population, the country has rapidly built substantial population immunity for rubella.
Dubbed “Calixcoca,” the treatment, developed by researchers at the Federal University of Minas Gerais, triggers an immune response that blocks cocaine and crack from reaching the brain. Last week, the project won the top prize of €500,000 at the Euro Health Innovation Awards for Latin American medicine.
The researchers from the University of Cambridge found that, on its own, the blood test could diagnose up to 30% of patients with BD, but combining it with the online psychiatric assessment significantly improved the diagnosis rate, especially in people whose diagnosis was not obvious.
